Acemi respondió a informes de Adres sobre medicamentos y atención médica, en medio del debate por ajuste a la UPC

diciembre 20, 2025

TL;DR

Acemi calls for Adres to officially request information from stakeholders for validation before publishing contrast results.
Discrepancies in deceased patient records can be attributed to updates in vital status, billing cycles, administrative closures, home dispensations, prospective payment models, and duplicate document entries.
Acemi expressed concern over the potential open access disclosure of sensitive patient data, including diagnoses and costs, emphasizing the confidential nature of medical history.
Increases in medication quantities and costs are linked to expansions in the Health Benefits Plan (PBS) and regulatory changes that moved technologies to UPC funding.
Differences in medication reporting between databases may stem from purchase/dispensation lags, varying reporting structures, and reporting responsibilities in Sismed.
Acemi requested that normative effective periods and permitted margins/logistics be considered when evaluating data.
The association is open to technical dialogues with Adres and the Ministry of Health and seeks access to anonymized information for improved analysis.
Acemi stated that decisions regarding UPC must be based on robust evidence and guarantee processes to enhance transparency and sustainability.

Continuar leyendo el artículo original